By PPN News Staff
The FDA granted a new indication for dupilumab (Dupixent, Regeneron) for children ranging from 6 months to 5 years of age with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
This is the first biological medication for AD approved for children in this age group.